Herein, we use gnotobiotic mice and a series of microbial colonization studies to show that microbial cutC-dependent TMA/TMAO production is sufficient to transmit heightened platelet reactivity and thrombosis potential in a host. Specifically, we examine in vivo thrombosis potential employing germ-free mice colonized with either high TMA-producing stable human fecal polymcrobial communities or a defined CutC-deficient background microbial community coupled with a CutC-expressing human commensal±genetic disruption of its cutC gene (ie, Clostridium sporogenes ΔcutC).
D
uring the past decade, a critical role for gut microbiota in both human health and disease has been established. [1] [2] [3] [4] A growing number of mechanistic studies have shown that direct microbial transfer from donor to recipient can facilitate transmission of disease-associated phenotypes, susceptibility for development of diseases, and even responses to therapy. [5] [6] [7] [8] [9] [10] [11] [12] Microbial transplantation studies allow for a clear demonstration of transmission of a host phenotype or disease susceptibility, providing strong evidence in support of a causal contribution of gut microbiota in host physiological processes and disease risks. Follow-up studies have, therefore, naturally begun to shift in focus toward understanding what microbial genes, gene products, and potential downstream metabolic products derived from microorganisms are interacting with and impacting the host. 7, 13 
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One gut microbiota-dependent metabolite, trimethylamine N-oxide (TMAO), has garnered significant attention because of its involvement in cardiovascular disease (CVD) development, enhanced platelet reactivity, and thrombosis potential. 7, [14] [15] [16] Numerous animal models and clinical studies support a role for TMAO in CVD development. Plasma levels of TMAO in multiple large-scale clinical studies are independently associated with incident CVD development and adverse event risks. 7, [14] [15] [16] The metaorganismal pathway resulting in TMAO generation is initiated by ingestion of nutrients rich in a Western diet (phosphatidylcholine, choline, and carnitine) and their subsequent use by gut microbes to produce the waste product trimethylamine (TMA). After absorption from the gut into the portal circulation, TMA is rapidly delivered to the liver where it is oxidized to form TMAO by a cluster of hepatic enzymes-the FMOs (flavin monooxygenases).
17 FMO3 serves as the major enzyme catalyzing the conversion of TMA into TMAO in both rodents and humans. 17 Animal studies employing genetic suppression of FMO3 demonstrate alterations in sterol, bile acid, and metabolic phenotypes relevant to vascular disease. [18] [19] [20] Multiple recent meta-analyses have reviewed available clinical studies investigating TMAO and CVD risks and concluded that elevated TMAO levels are dose-dependently associated with CVD and mortality risks. [21] [22] [23] Moreover, animal model studies using nonlethal inhibitors of microbial TMA production from choline demonstrate inhibition in diet-dependent atherosclerosis 24 and, more recently, thrombosis susceptibility. 25 Thus, there is substantial interest in studies examining potential gut microbial participants in TMA and TMAO generation, and demonstration of their potential involvement in disease processes relevant to CVD.
Choline represents a common abundant nutrient precursor for gut microbiota-dependent TMA production in omnivores and vegans/vegetarians owing to the high concentration of phosphatidylcholine and choline in bile. 26 Balskus et al 27 first identified a bacterial gene cluster in human gut isolates-the cut gene cluster-which promotes anaerobic choline metabolism via 2 cut gene products, catalytic and regulatory polypeptides encoded by the cutC/D (choline utilization C/D) genes, respectively. Present in a phylogenetically diverse range of sequenced human gut bacteria, the presence of predicted cutC/D genes within human gut microorganisms is correlated with their ability to grow on choline and promote the choline→TMA transformation (ie, choline TMA-lyase activity). [28] [29] [30] Use of synthetic microbial communities has demonstrated the presence or absence of choline TMA-lyase activity is sufficient to regulate microbial choline utilization and subsequent TMAO accumulation. 29, 30 However, to date, no studies have directly demonstrated that the presence of the microbial cutC gene can impact platelet function and thrombosis potential in the host nor have human fecal transplantation studies been used to transmit choline TMA-lyase activity and thrombosis potential into a recipient. Herein, we use genetically defined synthetic microbial communities, as well as polymicrobial fecal communities of human origins, to demonstrate that functional CutC levels in the intestinal microbiota can dose-dependently transmit enhanced platelet reactivity and heightened thrombosis potential within a host. Our studies suggest that global functional inhibition of gut microbial CutC represents a potential therapeutic approach for the treatment or prevention of CVD.
Methods
The authors declare that data and methods used in support of the findings presented in this study will be made available from the corresponding author on reasonable request.
Sequencing data sets used for community composition analysis are publicly available through NCBI's Sequence Read Archive Database under BioProject PRJNA480401.
Human Studies
All subjects involved in studies presented gave informed consent with protocols approved by either the Cleveland Clinic Institutional Review Board or the Institutional Review Board of the University of Wisconsin-Madison. Human fecal samples (and accompanying plasma samples) used for microbial transplantation studies in the main article were collected as part of the Carnival study (NCT01731236; http:// www.clinicaltrials.gov), where results were previously reported in aggregate (group wise) form. 7 Healthy donors were prescreened and 
Novelty and Significance
What Is Known?
• Trimethylamine N-oxide (TMAO) is a metaorganismal metabolite that is dose dependently associated with major adverse cardiovascular events.
• Microbial production of trimethylamine (TMA) is required for significant (and sustained) TMAO accumulation.
What New Information Does This Article Contribute?
• The presence of a functional gut microbial cutC (choline utilization C) gene is sufficient to impact platelet response and thrombosis potential in the host.
• Functional CutC levels in the intestinal microbiota can be transmitted by fecal transplantation, thereby enhancing platelet reactivity and thrombosis potential within the recipient.
• Inhibition of microbial CutC may serve as a promising therapeutic approach to favorably impact cardiovascular disease pathogenesis and reduce thrombotic potential.
The gut microbiome is associated with an ever-increasing array of diseases. Before novel therapeutic strategies can leverage these discoveries, a mechanistic role of specific gut microbiota-dependent pathways in both host physiology and disease pathogenesis must be understood. Numerous studies suggest the metaorganismal TMAO pathway is a promising target for such endeavors. In animal models, TMAO has been shown to promote platelet hyperresponsiveness. It is, therefore, important to establish which host phenotypes can be manipulated to alter gut microbial TMAO production, both at the microbiota gene and the enzyme activity level. TMAO synthesis is dependent on microbial formation of TMA, which is mediated in large part by the microbial enzyme choline TMA-lyase CutC. Herein, we establish the presence and expression of the gut microbial cutC gene may be transmitted from donor to recipient, transferring enhanced TMA and TMAO generation, platelet responsiveness, and thrombosis potential. Collectively, these findings support targeting the microbial choline TMA-lyase pathway for the treatment of atherothrombotic heart disease. October 26, 2018
confirmed to have no preceding history of antibiotic or probiotic use within 3 months of study enrollment. Additional exclusionary criteria for this study included (1) a significant chronic illness or end-organ dysfunction, (2) ingestion of yogurt within the past 7 days, (3) chronic gastrointestinal disorders, (4) having undergone bariatric procedures, or (5) pregnancy. Subjects (46±5 years of age; 40% men; nonsmokers without hypertension, diabetes mellitus, or CVD) were given oral choline supplementation (choline bitartrate, 500 mg BID; equivalent to 450 mg total choline per day) for 2 months with monthly fasting blood and stool collections. From these studies, differences in diet were highlighted previously, and thus only omnivores are shown here. Of these, 2 subjects (corresponding to high and low plasma levels of TMAO) were selected to serve as donors for human fecal microbial transplantation studies. These human donors were approximately matched based on age (51 and 59 years of age), sex (women), and BMI (30.8 and 31.7). In separate fecal microbial transplantation studies, human feces recovered from a high versus low TMAO-producing community when transplanted into germ-free mice were provided from the University of Wisconsin-Madison. 31 These validation human fecal microbial transplant studies (reported in Online Figure I ) followed the same experimental design and used frozen human donor fecal samples that were previously utilized as colonization material for mice in method studies describing and characterizing a new fecal microbial collection and processing protocol.
31

Human Fecal Microbial Transplant Studies
Stool samples from human donors collected at the Cleveland Clinic were stored for future humanization studies as fecal slurries (0.15 g/ mL) in 10% glycerol at −80°C. Germ-free C57BL/6J mice (8-10-week old; female; purchased from Jackson Laboratory) were colonized with 200 µL of a 5× dilution of the above stock by oral gavage. Mice were transferred to a chemically defined diet supplemented with 1% w/w choline (Envigo TD.09041) the morning of fecal transplantation. One week after colonization, blood was collected for use in in vitro aggregometry studies, or mice were utilized for in vivo thrombosis. 7 On completion of studies, tissues were collected and immediately frozen at −80°C. After colonization, the investigator was not blinded from treatment groups to allow testing first on the low TMA-producer colonized mice before testing on the high TMA-producer colonized mice to avoid cross contamination. Fecal samples for the validation studies were collected using the Fecal Aliquot Straw Technique and stored at −80°C until use. 31 Validation animals were colonized with 200 µL freshly prepared fecal slurry using Mega Medium.
Construction of cutC Directed Insertional Mutants That Are Enzymatically Null
Disruption of the cutC gene in Clostridium sporogenes (CLOSPO_02864) was accomplished using the ClosTron mutagenesis procedure as reported previously. 32, 33 The cutC targeting DNA sequence was cloned into the shuttle plasmid pMTL007C-E2 to make the retargeted vector pMTL007C-E2::Csp-cutC. The retargeted pMTL007C-E2::Csp-cutC plasmid was conjugated into C sporogenes and plated onto TYG agar plates supplemented with D-cycloserine (250 µg/mL) and thiamphenicol (15 µg/mL).
33
Antibiotic resistant colonies were verified by diagnostic polymerase chain reaction (PCR) for harboring the plasmid of interest. PCRpositive colonies were spread onto TYG agar plates supplemented with erythromycin (5 µg/mL) before selection again on TYG plates supplemented with D-cycloserine and erythromycin. Screening for intron insertion was performed after bacterial genomic DNA was extracted using the Zymo Fungal/Bacterial DNA Extraction Kit. Extracted DNA was used for diagnostic PCR using the primer set (Fwd: 5′-CGTGTTCATAAGGAACTTGCAC-3′; Rev: 5′-GCTTTTCTCTCGATTATACC-3′), which results in a ≈1000 bp product for the WT (wild type) cutC DNA sequence and ≈3200 bp product for the directed insertional mutant containing the intron. PCR-verified directional insertion clones were confirmed to not produce TMA by stable isotope dilution liquid chromatography with tandem mass spectrometry (LC/MS/MS) analyses. 34 
Gnotobiotic Mouse Husbandry
All experiments involving mice were performed using protocols approved by the Cleveland Clinic Animal Care and Use Committee. Gnotobiotic C57BL/6 mice aged 8 to 10 weeks were provided from the University of Wisconsin-Madison. Animals were shipped to the Cleveland Clinic Lerner Research Institute gnotobiotic facility and on arrival were maintained in sterile isolators and equilibrated onto the defined choline diet for 2 weeks before and after simple randomization and colonization where appropriate. In some mice, as indicated, TMAO was provided in filter sterilized drinking water (0.2% w/w TMAO). Food and water were provided ad libitum and lights maintained on a strict 12-hour light/dark cycle. Male mice were not utilized in these studies because of the known reduced hepatic expression of FMO enzymes in adult males, leading to a significant decrease in the capacity to generate TMAO.
Gnotobiotic Mouse Colonization
Microbial strains used to colonize mice were grown as monocultures on Mega Medium agar plates anaerobically for 48 to 72 hours at 37°C. Single colonies were then inoculated into 3 mL of Mega Medium and grown anaerobically at 37°C until late log phase. Strains belonging to the same treatment group were combined in an equal volume ratio in a Hungate tube. Germ-free, C57Bl/6 8-to 10-week-old mice were inoculated by oral gavage with 200 µL of mixed bacterial culture inside the gnotobiotic isolator or biological safety cabinet. At the time of euthanization, tissues were immediately collected, frozen, and stored at −80°C. After colonization, the investigator was not blinded from treatment groups to avoid cross contamination.
In Vitro Aggregometry
Mice were anesthetized, and platelets were collected from whole blood as described previously. 7 Platelets were counted and concentrations adjusted to 2×10 8 cells per mL with platelet-poor plasma as the diluent. CaCl 2 and MgCl 2 (both 1 mmol/L final concentration) were added immediately before platelet aggregation studies. Platelet aggregation in response to 1 μM ADP was assessed in triplicate at 37°C in a dual-channel Type 500 VS aggregometer (Chrono-log Corporation, Havertown, PA) with stirring at 1000 rpm. Sample sizes of animals are indicated in the figures. Instances of mismatched samples are because of the inability to obtain a complete blood sample.
Choline TMA-Lyase Activity Assay
Choline TMA-lyase enzyme activity was determined by quantifying d9-TMA production from d9-choline substrate using stable isotope dilution LC/MS/MS analyses as described previously. 34 Activity is shown as pmol d9-TMA per milligram tissue per hour. Sample sizes are indicated in the figures. Instances of mismatched samples are because of incomplete reaction. Samples were identified by code number only, and investigators remained blinded to sample identity during laboratory analyses.
Hepatic FMO Activity Assay
Total liver FMO activity was determined by quantifying flavin-dependent d9-TMAO production from d9-TMA substrate using stable isotope dilution LC/MS/MS analyses 14 with minor modifications. Briefly, livers samples were homogenized in 10 mmol/L HEPES, pH 7.4, containing protease inhibitor cocktail. Protein concentration was determined from supernatants by BCA protein assay. 
Carotid Artery FeCl 3 Injury Thrombosis Assay
Mice were then anesthetized and subjected to a common carotid artery injury by application of 10% FeCl 3 for 1 min, as described previously. 7 Rhodamine 6G (100 µL; 0.5 mg/mL) was injected directly into the right jugular vein to label platelets. Thrombus formation was observed in real time using intravital fluorescence microscopy equipped with video recording. Time to cessation of blood flow through clot formation for all studies was determined by visual inspection by 2 different investigators. End points were set as cessation of blood flow for 30 seconds to 30 minutes.
Microbial Community Analysis
Microbial DNA from transplanted mice was extracted following MO BIO PowerSoil-htp 96 Well Soil DNA Isolation Kit procedure with an additional incubation at 65°C for 10 minutes before plate shaking. The 16S rRNA V4 hypervariable region was amplified with barcoded primers in triplicate using the 5 PRIME HotMasterMix (VWR International). 35 Products were quantified with Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher), and samples were combined in equal amounts (≈250 ng per sample) to be purified with the UltraClean PCR Clean-Up Kit (MO BIO). Pooled amplicons were sequenced on the Illumina HiSeq platform over 2 lanes to generate single-end reads.
Raw sequences were processed with the open-source Quantitative Insights Into Microbial Ecology software package, version 1.9.1, to produce demultiplexed and quality-controlled sequences. 36 Samples were binned into OTUs using the pick_closed_reference_otus.py script at 97% similarity using SUMACLUST against a Greengenes reference database. 37, 38 Microbial community patterns were visualized with principal component analysis using unweighted UniFrac distance measure on samples rarefied to 267 600 reads per sample in an effort to reduce the effect of unequal sequencing depth. 39 Treatment groups had similar multivariate homogeneity of dispersions and so were compared using the nonparametric PERMANOVA test with the adonis function. Hierarchical clustering by unweighted pair group method with arithmetic mean was performed using the unweighted UniFrac distance matrices in Quantitative Insights Into Microbial Ecology. Heatmap containing OTUs at 0.005% relative abundance by sample were organized by row using principal component analysis with unweighted UniFrac distance measure. All graphs and analyses were performed in R using the phyloseq package v 1.19.1 and the associated dependencies. 40 Comparison of specific microbial genera abundance with TMAO or aggregation levels were determined by unpaired t test with Welch correction. Heat maps were generated with the R statistical package with DESeq, vegan, and vegan programs.
Bacterial communities resulting from inoculation of germ-free animals with synthetic communities were analyzed using previously reported methods. 30 Instances of mismatched samples are because of either animals who died before terminal measurement completion being sequenced or euthanized animals failing to properly sequence.
Statistics
Human data was determined to be normally distributed by the D'Agostino and Pearson omnibus normality test. Pearson correlation coefficient for normally distributed data and Spearman correlations for non-normally distributed data were used to analyze associations between quantitative variables. Student t tests and 1-way ANOVAs, followed by multiple comparison post tests, were completed in Prism and are detailed in the respective figure legends. For all statistical tests, P <0.05 was considered significant.
Results
Transmission of Both TMA/TMAO Production and Thrombotic Risk Phenotypes Through Human Fecal Transplant to a Germ-Free Recipient
We recently described the involvement of TMAO in promoting heightened thrombosis potential in vivo by demonstrating TMAO directly induces heightened responsiveness in isolated platelets to multiple agonists like ADP, thrombin, and collagen. 7 In the present studies, we initially sought to test whether human fecal transplantation could transmit gut microbial choline TMA-lyase activity and thrombosis potential into a recipient. Thus, our experimental design involved the use of germ-free mice as recipients that were colonized by human fecal microbial transfer from subjects with high versus low TMAO levels and then subsequent testing to determine whether recipients showed heightened gut microbial (cecal) choline TMA-lyase activity, circulating TMA and TMAO levels, and correspondingly enhanced platelet reactivity ( Figure 1A) . For selection of a stable polymicrobial community to serve as donor, we utilized fecal samples recovered during the conduct of a recently reported human intervention study in which choline supplements (choline bitartrate, 500 mg orally BID) were shown to elevate TMAO and foster-enhanced platelet reactivity as monitored by platelet aggregometry in subjects 41 ( Figure 1B ). Subjects on an omnivorous diet showed significant variation in the extent of TMAO elevation. Plasma levels of all subjects at baseline versus 1-and 2-month time points are shown in Figure 1B , and the donors and time points selected to represent low versus high TMAO are indicated (fecal samples corresponding to plasma TMAO of 2.1 and 34.2 µmol/L, respectively; Figure 1B) . 41 Choline TMA-lyase activity measured (from d9-choline substrate) in the human fecal donors selected was 0.4±0.5 and 11.1±2.2 pmol d9-TMA per mg tissue per hour for the low and high donors, respectively. Feces were transplanted as a slurry via gastric gavage into germ-free mice on a choline diet as described under Methods. After transplantation, colonized mice were euthanized, whole blood and tissues recovered, and multiple indices of the TMAO metaorganismal pathway examined, along with platelet aggregation responses in platelet-rich plasma using a submaximal (1 µmol/L) level of ADP ( Figure 1C through 1F) . Notably, significantly elevated levels of cecal choline TMA-lyase activity (P=0.006), plasma TMAO levels (P=0.011), and platelet aggregation responses (P=0.0005) were observed in recipients of the high (versus low) TMAO donor feces. Examination of hepatic total FMO activity in both groups of recipients showed no significant difference (P=0.68; Figure 1D) .
In an independent set of human fecal microbial transplantation studies, we sought to replicate these findings. Human fecal samples used for these studies were collected at the University of Wisconsin-Madison and were previously characterized for their TMA/TMAO-producing capacity. 31, 42 Direct measurement of the choline TMA-lyase enzymatic activity in these donor samples showed 20.3±2.0 and 49.4±3.2 pmol d9-TMA per mg tissue per hour for the low and high donors, respectively (P<0.05). After transplantation, the recipient mice (maintained on high-choline diet) demonstrated significant differences in circulating TMAO levels with recipients of the high TMAO donor feces showing nearly double the TMAO level of that observed in recipients of the low TMAO donor feces (P<0.0001; Online Figure IA) . Similarly, cecal microbial choline TMA-lyase activity measured in the murine recipients was significantly different (P=0.01; Online Figure IB) . Faster clot formation October 26, 2018 was observed in the high TMAO recipients, and representative images of clot formation at different times after injury between the recipient groups are shown in Online Figure ID . The time to cessation of blood flow was also significantly decreased in mice colonized with the high TMAO donor (P<0.0001; Online Figure IC) .
In a final series of analyses, we examined the dose-dependent relationship between plasma TMAO levels and indices of platelet function and thrombosis potential in each of the human fecal transplantation studies. Notably, platelet aggregation responses within the recipients in the first study showed a highly significant dose-dependent positive association (r=0.75, P=0.003; Figure 2A) . Similarly, examination of the in vivo thrombosis potential in recipients of the second human fecal transplantation study, as monitored by time to cessation of blood flow in the carotid artery injury model, revealed a significant dose-dependent relationship (r=−0.75, P=0.0009; Figure 2B ).
Microbial Composition Analyses of Human Fecal Transplantation Studies
We examined microbial community structure via 16S rRNA gene sequencing analyses of both human fecal donor and murine cecal recipient communities in the initial human fecal transplantation experiment, as described under Methods. Notably, principal component analysis revealed the microbial phylogeny of the high TMAO versus low TMAO transplantation resulted in significant differences in the murine recipient microbiome ( Figure 3A) . Hierarchical clustering analyses further established the defined separation of the recipient mice based on donor TMAO status ( Figure 3B ). These results provide evidence of transmission of multiple features of high TMAO versus low TMAO microbial communities. Microbial taxa whose proportions are characteristic of the high TMAO versus low TMAO communities (in recipients) were discerned through linear discriminant analysis ( Figure 3C) . A heat map of relative proportions of taxa in recipients classifies the Figure 1 . Transmission of thrombotic risk phenotypes through human fecal transplant to a germ-free recipient. A, Scheme illustrating fecal microbial transplant study design. Germ-free C57Bl/6J mice were colonized by oral gavage with a fecal microbial community from (B) human subjects with either high or low plasma trimethylamine N-oxide (TMAO) levels (donors shown with dark symbols along with corresponding TMAO levels). Recipient mice were maintained on a choline diet. Five days post-transplant, blood was collected, tissues harvested, and (C) cecal choline trimethylamine (TMA) lyase activity was measured; (D) hepatic flavin monooxygenase activity was measured; (E) plasma TMAO was measured; and (F) platelet function was assessed by ex vivo monitoring of aggregation response to submaximal ADP (1 µM). P values were determined by 2-tailed unpaired t test with Welch correction.
colonized recipient mice based on donor microbiome (high versus low TMAO; Online Figure II) . The relative abundance of several characteristic (in linear discriminant analyses) microbial genera in the high TMAO colonized mice was observed to be significantly associated with both high plasma TMAO levels and increased platelet aggregation responsiveness ( Figure 3D through 3F) .
Microbial Colonization of a cutC Containing Human Commensal Within a Defined (ΔcutC) Microbial Community Transmits Into Recipient TMA/TMAO Generation, Heightened Platelet Responsiveness, and Enhanced Thrombosis Potential
We next sought to test whether colonization of germ-free mice with a human commensal that possesses the cutC gene and can produce TMA from choline in vitro confers altered platelet responsiveness and in vivo thrombosis potential in the host. Previous published studies examined a large panel of culturable human gut isolates for the production of d9(trimethyl)-TMA from d9(trimethyl)-choline and demonstrated that of those capable of producing TMA from choline in culture (n=8 of 79 screened), the majority (n=7 of 8) possessed components of the choline utilization gene cluster based on sequence homology. 29 Armed with this information, we utilized a core set of microorganisms (Bacteroides thetaiotaomicron, Bacteroides caccae, Bacteroides ovatus, Collinsella aerofaciens, and Eubacterium rectale) to serve as a synthetic Core community for transplantation studies because they had previously been shown to lack TMA production capacity from choline (TMA null). Indeed, when cultured anaerobically, both individually and in combination in the presence of d9-choline, we confirmed no detectable d9-TMA was produced ( Figure 4A) . In some mice, a single microorganism, C sporogenes, which possesses a predicted cutC gene and was previously shown to be capable of producing d9-TMA from d9-choline under anaerobic culture, was chosen to be added to this synthetic TMA-null Core community to form a TMA-producing community ( Figure 4A) . We thus colonized all germ-free mice with the TMA-null Core community of microorganisms and in the group indicated, also included C sporogenes. In an additional group, germ-free mice colonized with the TMA-null Core community were provided TMAO in sterilized drinking water, as described under Methods. After colonization, mice were maintained for 2 weeks on a high-choline diet, and blood, tissues, and cecum recovered for assessment of platelet function through aggregometry, and biochemical and microbiota composition analyses.
As expected, among the 3 groups, only mice cocolonized with C sporogenes demonstrated detectable cecal choline TMA-lyase activity ( Figure 4C ). On further examination of plasma, virtually no detectable TMAO (submicromolar) was observed in the TMA-null Core community colonized mice, compared with ≈100-fold higher levels of TMAO in the mice concomitantly colonized with C sporogenes or supplemented with TMAO via the drinking water ( Figure 4B, bottom) . Importantly, analyses of platelet aggregation results using submaximal (1 µM) ADP to stimulate platelet-rich plasma recovered from each group demonstrated increased platelet responsiveness in the C sporogenes cocolonized group similar to that observed in the TMAO supplemented group ( Figure 4B) . In additional control studies, liver tissue was recovered, and total hepatic flavin-dependent FMO activity was quantified. No significant differences were observed among all groups of mice ( Figure 4D ). These results support microbiota-dependent changes in the observed changes in TMAO levels and platelet function and not the host hepatic (FMO mediated) transformation of TMA→TMAO. In a final series of studies, microbial composition analyses were performed on cecal contents from each group of mice as described under Methods. Notably, C sporogenes represented only ≈0.2% of the total community ( Figure 4E) .
In a separate set of studies, we similarly colonized germfree mice with only the TMA-null Core community alone or in the presence of the TMA-producing C sporogenes, for the purpose of examining in vivo thrombosis potential. All mice were maintained in microisolators on high-choline diets for 2 weeks, and after FeCl 3 injury of the carotid artery, the rate of thrombus formation in vivo and the time to vessel occlusion were assessed as described under Methods. Figure 5A shows representative images at the indicated times after FeCl 3 -induced injury, as visualized using vital microscopy equipped with time lapse fluorescent camera to permit time-dependent quantification of fluorescently tagged platelets during clot formation and determination of the time of vessel occlusion (cessation of blood flow). As before, only mice colonized with both the synthetic Core community and C sporogenes demonstrated significant TMAO levels, with accompanying faster rate of clot formation and substantially shorter time to vessel occlusion (illustrative example, Figure 5A ). Quantitative analyses of all mice and images revealed over 100-fold higher plasma TMAO levels (P<0.0001) and significantly shorter (P=0.0002) time to vessel occlusion in the mice colonized with both the TMA-null Core community and C sporogenes ( Figure 5B) . Again, examination of choline TMA-lyase activity (d9-choline→d9-TMA) in cecum recovered post-colonization showed significant activity only within cecum recovered from recipients of the TMA-producing C sporogenes (P<0.0001; Figure 5C ). Moreover, quantification of total hepatic FMO activity (flavin-dependent conversion of d9-TMA→d9-TMAO in liver homogenates) in both groups of mice showed no significant difference between treatment groups (P=0.06; Figure 5D ). Microbial composition Each data point represents a sample from a distinct human donor or mouse recipient projected onto the first 3 principal coordinates (representing 89% of the total variance). B, Heirarchical clustering using unweighted pair group method with arithmetic mean of human donor and recipient mice reveals a relationship among recipient mice in which the mice colonized with the high TMAO donor cluster together and distinctly from the mice colonized with the low TMAO donor. Branch lengths indicate distance of separation based on unweighted UniFrac distance matrices. C, Linear discriminant analysis (LDA) effect size (LEfSe) identified cecal taxa from mouse characteristic in low TMAO recipients (empty bars) and high TMAO recipients (filled bars). D-F, The relationship of specific indicated genera abundance to plasma TMAO levels or aggregation values in low TMAO recipient mice (empty dots; n=6) and high TMAO recipient mice (filled dots; n=7). P values were determined by unpaired t test with Welch correction.
analyses of the recipient groups of mice post-colonization again showed C sporogenes represented only ≈0.08% of the total community ( Figure 5E ). Thus, despite representing only a small fraction of the overall community inhabitants, the addition of C sporogenes accounted for all measured functional differences observed (ie, elevated choline TMA-lyase activity, elevated TMAO levels, heightened platelet responsiveness as monitored by platelet aggregometry, and heightened in vivo thrombosis potential as monitored by both thrombus rate of formation and time to vessel occlusion after injury). A, Capability to produce d9-TMA from d9-choline substrate in individual microbes or in combination was determined in vitro. B, C57Bl/6 germ-free mice colonized by gastric gavage with a core community±C sporogenes (TMA producer). The non-TMA-producing core microorganisms consist of B caccae, B ovatus, B thetaiotaomicron, C aerofaciens, and E rectale. Core+TMAO mice received TMAO in drinking water (0.2% w/w TMAO). All mice received a choline diet. Fourteen days post-transplant blood was collected, platelet-rich plasma recovered and ex vivo platelet aggregation response to ADP (1 µM) was measured. C, Cecal choline TMA-lyase activity and (D) hepatic FMO (flavin monooxygenase) enzyme activity were assessed as described under Methods. E, Cecal microbial community composition was determined sequencing of mouse cecum, as described in Methods. Two mice from the Core+C sporogenes group and 1 mouse from the Core+TMAO group failed to sequence. All P values shown were determined by 1-way ANOVA with Tukey multiple comparison post test (B-E). October 26, 2018
Mice Colonized With a C sporogenes ΔcutC Strain Do Not Accumulate TMAO and Exhibit Reduced Thrombosis Potential
Beyond cutC, additional microbial genes with distinct catalytic mechanisms have been identified that can catalyze the transformation of choline or other TMA-containing nutrient precursors into TMA. 34, 43 Although the cut gene cluster appears to be the most abundant choline TMA-lyase known among sequenced human gut commensals, and genome screening of C sporogenes reveals that the only predicted choline utilization gene it harbors is cutC, we thought it prudent to perform additional studies to ensure that CutC within C sporogenes was responsible for the heightened TMAO and thrombosisrelated phenotypes (platelet aggregation responses, thrombus rates of formation) in the germ-free mice colonized with the microbe. Directed insertional disruption mutation of the cutC Figure 5 . Microbial colonization of a cutC (choline utilization C/D) containing human commensal transmits trimethylamine (TMA)/trimethylamine N-oxide (TMAO) generation and heightens thrombosis potential. Germ-free C57Bl/6 mice were colonized by oral gavage. Core mice received non-TMA-producing B caccae, B ovatus, B thetaiotaomicron, C aerofaciens, E rectale. Core+C sporogenes mice received the additional TMA-producing microorganism. All mice maintained on a choline diet. A, Fourteen days after colonization, thrombosis potential (FeCl 3 carotid injury model) and plasma TMAO levels were assessed. Example clot formation images are shown with average plasma TMAO±SD values. B, Time to cessation of blood flow was determined as described in Methods. C, Cecal choline TMA-lyase activity and (D) hepatic FMO (flavin monooxygenase) enzyme activity were assessed as described under Methods. E, Cecal microbial community composition was determined by sequencing of mouse cecum, as described in Methods. One animal in the Core group dead before terminal measurements could be completed was still used in sequencing analysis. P values were determined by unpaired t test with Welch correction. gene in C sporogenes was, therefore, performed, as described under Methods, to enable studies to directly compare results observed between this human commensal in WT form, versus C sporogenes lacking a functional CutC enzyme (ΔcutC). Examination of the growth rates of C sporogenes (WT) versus C sporogenes (ΔcutC) in anaerobic culture in choline containing media shows a modest but detectable reduction in growth rate ( Figure 6A , left) and complete absence of capacity to generate d9-TMA from d9-choline ( Figure 6A , right). After confirming that the C sporogenes (ΔcutC) was viable yet lacked choline→TMA transforming activity, we performed additional microbial transplantation studies in germ-free mice as recipients. Three groups of mice were examined and maintained in isolators after colonization. All 3 groups received the synthetic TMA-null Core community. One group was cocolonized with C sporogenes (WT), whereas the second group received the TMA-null C sporogenes (ΔcutC). The third group of mice remained colonized with only the Core community but received TMAO in drinking water. Two weeks after colonization, the mice were examined for quantification of in vivo thrombus rate of formation and time to cessation of blood flow after FeCl 3 -induced common carotid artery injury. On euthanization, blood and tissues were harvested for biochemical and gut microbe composition analyses. As seen in Figure 6B , visual inspection of images captured with the fluorescence camera on vital microscope platform shows faster rate of clot formation and shortened time to vessel occlusion in the representative mouse colonized with Core+C sporogenes (WT) and Core+TMAO (drinking water), relative to the Core+C sporogenes (ΔcutC) group. Quantification of plasma TMAO levels among all mice within each group again showed elevated levels in both the mice colonized with the Core+C sporogenes community and the Core mice supplemented with TMAO in the drinking water. Importantly, the germ-free mice colonized by the TMA-null Core community+C sporogenes (ΔcutC) showed negligible levels of TMAO. Moreover, quantification of the time to cessation of blood flow in these groups of mice revealed disruption of cutC both eliminated the heightened plasma TMAO levels otherwise observed in the other groups and markedly reduced the in vivo rate of thrombosis (ie, the time to cessation of blood flow, or the occlusion time, was substantially longer; P<0.001; Figure 6C ). As expected, examination of cecal choline TMA-lyase enzyme activity in recovered tissues from the different mice groups showed significant and detectable levels only among the group colonized with C sporogenes (WT) and not the cutC insertional mutant (C sporogenes, ΔcutC) or the Core community only (+TMAO in drinking water; Figure 6D ). No differences in hepatic total FMO activity were observed among the 3 groups ( Figure 6E ). Finally, examination of the cecal microbial community compositions among each group of colonized mice showed C sporogenes (WT) and C sporogenes (ΔcutC) represented similar proportions that again only represented quantitatively a modest component of the entire community (≈0.1% of total; Figure 6F , right).
Discussion
Despite the clinical importance of the microbiome in human physiology and potential diseases, such as CVD, we are only just beginning to appreciate potential mechanisms through which this occurs. To date, research has primarily focused on defining the composition of microorganisms present in the microbiome, although efforts to directly functionally interrogate the participants involved and elaborate the chemical mediators are of intense interest. To make matters more complex, it is also recognized that many of the vital functions of the gut microbiome are redundant, and such is likely also the case for undesirable functions of the microbiome. Herein, we use a systematic approach to study the potential role of a gut microbial enzyme impacting the host in a directed and organized fashion. Our studies provide direct experimental evidence for a link between CutC within gut microbiota and potential to alter platelet function and thrombosis potential in the host. Specifically, we demonstrate that transplantation of human fecal polymicrobial communities from subjects with substantial differences in specific activity of functional CutC levels can differentially transmit TMA and TMAO generation within the host, with accompanying heightened platelet aggregometry responsiveness (with higher choline→TMA and TMAO levels), and in vivo thrombosis potential, as monitored by the carotid artery FeCl 3 injury model. Moreover, we show that gnotobiotic mice colonized with a defined synthetic microbial community comprised of human gut commensals lacking TMA generation (aka the TMA-null Core), in the absence versus presence of C sporogenes-a TMA generating human gut commensal that contains CutC-can transmit TMA/TMAO generation, heightened platelet responsiveness to agonist, and both enhanced thrombus rate of formation and shortened vessel occlusion time in vivo. It is important to note that the proportion of C sporogenes was repeatedly observed to occupy only a relatively small overall niche (≈0.1%) within the gut microbial community, yet capable of driving these critical gain-of-function phenotypes. Finally, microbial transplantation studies employing C sporogenes (ΔcutC) in which a group II intron was used to mutate the cutC gene is shown to still result in comparable engraftment of C sporogenes relative to the WT strain within the gut microbial community. Not only did engraftment of C sporogenes ΔcutC functionally eliminate TMA and TMAO production within the host but it also eliminated the otherwise observed choline diet-dependent prothrombotic phenotype observed within germ-free mice recipients colonized with a TMA-null Core community+functional CutC containing C sporogenes (WT). The presented studies thus confirm gut microbiota possessing CutC specifically, and choline TMA-lyase activity in general, can contribute to heightened TMAO levels, altered platelet function, and enhanced thrombosis potential within a host. The studies also suggest that functional CutC is not essential to microbial (C sporogenes) fitness because the ΔcutC mutant shows comparable engraftment and overall community proportion relative to the WT strain. The present study adds to the growing body of literature providing a strong argument for the targeting of the TMAO metaorganismal pathway. Further, the present studies suggest global functional inhibition of microbial CutC may serve as a therapeutic approach for favorably impacting risk for CVD and thrombosis potential. Although the present studies have been focused on TMAO and its effect on platelet responsiveness and thrombosis risk, the general design and approach taken in the present studies can be broadly used for other CVD and metabolic phenotypes associated with TMAO (eg, adverse ventricular remodeling and heart failure, [44] [45] [46] renal functional decline, and chronic kidney disease 47, 48 ). Indeed, the present approach may serve as a template to apply toward examination of other microbial or metaorganismal pathways implicated as a potential participant in physiological processes or disease-associated phenotypes.
